💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Mankind Pharma Limited is an India-based pharmaceutical company. The Company is engaged in developing, manufacturing, and marketing a range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A middling, steadily growing business, fully valued.
Mankind Pharma is scored on the pharma / healthcare framework. It keeps a healthy 13.2% of every rupee of sales as net profit. Those profits are backed by real cash — operating cash flow runs 1.61× reported profit. Free cash flow is worth about 2.8% of its market value.
Over the last 3 years revenue compounded at 18%/yr and profit at 14%/yr. Book value itself has compounded 30%/yr — the hallmark of a genuine compounder. Return on equity is a healthy 12.8%. In the latest quarter profit grew 25% versus the prior quarter.
At 55× earnings, the stock sits at the 75th percentile of its own 3.5-year range — the expensive end of where it has historically traded. Today's price already implies ~20%/yr earnings growth sustained for a decade — a demanding bar. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 46.35 | — | — |
| P/B | 5.97 | 4.1 | worse |
| EV/EBITDA | 25.26 | 19.33 | worse |
| ROE | 12.76 | — | — |
| ROCE | 14.68 | 14.41 | better |
| ROA | 7.82 | 1.64 | better |
| Quick Ratio | 0.74 | — | — |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
Revenue has grown every year across all 4 financial years shown. 18% CAGR over 3 years — steady double-digit compounder. Growth is decelerating — latest year grew slower than the year before.
Profit is on a 2-year growth streak. Revenue is outpacing profit (18% vs 14%) — costs are rising faster than the top line.
Operating margin has compressed from 19% to 16% — costs or competition are eating into profitability.
ROE at 12% — modest; the capital isn't working hard. Capital efficiency declining — ROE down 5pp.
EPS dropped in the latest year despite possible profit changes — dilution or a profit dip could be at play. 13% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Cash conversion at 1.6× PAT — earnings are well-backed by cash; strong accrual quality. Heavy investing spend every year, but operations generate enough to cover it — the business self-funds its growth.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue rose 9% sequentially — momentum is building. Run-rate stepping up — recent quarters average 18% above earlier ones.
Profit jumped 25% QoQ — check if this is operating leverage or a one-off item. Quarterly net margins are expanding (11% → 16%) — profitability per rupee of revenue is improving.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.5y median.
Promoters hold 72.6% — heavily owner-operated with strong skin in the game. MF holding up 2.0pp — domestic institutional discovery underway.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.